Cara Therapeutics | CARA - Current Liabilities


Cara Therapeutics reported $11.26M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 305.52M 28.41M Mar/2026
Alterity Therapeutics Limited AUD 1.73M 2.77M Dec/2025
Cara Therapeutics USD 11.26M 216K Mar/2026
Cassava Sciences USD 40.11M 3.72M Mar/2026
Chugai Pharma JPY 392.19B 64.49B Jun/2026
Cipla INR 70.14B 7.16B Mar/2026
Clal Biotechnology ILS 6.66M 3.75M Dec/2023
Compugen USD 22.04M 533K Mar/2026
CSL USD 4.61B 207M Dec/2025
Grifols EUR 2.37B 156.97M Dec/2025
Halozyme Therapeutics USD 363.21M 186.12M Mar/2026
J&J USD 54.9B 2.82B Jun/2026
Neurocrine Biosciences USD 874.5M 42.8M Jun/2026
Pacira USD 108.79M 11.8M Mar/2026
Pfizer USD 32.65B 1.7B Jun/2026
RedHill Biopharma USD 19.22M 3.07M Dec/2025
Supernus Pharmaceuticals USD 347.38M 26.55M Jun/2026
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025